GlassScriptPhysician profile
James Edward Alonso
NPI 1063506566
$12,769.02
in general payments reported to CMS, 2019-2025
59 companies · $809 in 2025
The $809 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,336 · 2020: $1,120 · 2021: $1,568 · 2022: $1,791 · 2023: $2,101 · 2024: $4,044 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,887 · Education: $66.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,886.99 |
| Education | $66.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,280.45 | 2020-2025 | Botox, Ubrelvy, Qulipta |
| Allergan, INC. | $1,882.73 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $773.74 | 2019-2024 | Qelbree |
| Pfizer INC. | $624.70 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $611.37 | 2019-2025 | Rytary, Crexont |
| Novartis Pharmaceuticals Corporation | $506.47 | 2019-2025 | |
| Lilly USA, LLC | $473.97 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Ucb, INC. | $445.37 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Argenx US, INC. | $347.54 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $335.24 | 2019-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $333.04 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $317.83 | 2022-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $235.60 | 2019-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $218.38 | 2019-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $211.35 | 2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Alonso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.